Hu X., Wang S., Fu S., Zeng J., Wu Y., Gong L., Cao Y., Zhang Y., Han Y., Ouyang H., Xiong Y., He X., Cheng J., Zou S., Chen Z., Tao L., Meng J., Huang L., Yuan Q., Peng Z., Li Q. Discovery of XRF-1021, a 2,4-disubstituted-5-fluoropyrimidine derivative as a homeodomain-interacting protein kinase 2 inhibitor for the treatment of chronic kidney disease. Eur J Med Chem, 2026, 302(Pt 2): 118353.
上一条：Zhao R., Zhao C., Gao R., Cai Q., Li Q., Hu L. Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics. Drug Discov Today, 2025, 30(1): 104287.
下一条：Yao M., Wu Y., Hu X., Feng C., Xu J., Chen Z., Li Q. Design, synthesis, and in vitro anti-renal fibrotic effects of imidazopyridazine-based homeodomain-interacting protein kinase 2 inhibitors. Bioorg Med Chem, 2026, 132: 118456.
